Origin Biosciences Completes $45 Million Series B1 Financing to Accelerate Global Clinical Development of Core Pipeline

Shanghai, China, February 28, 2023 – Oricell Therapeutics Holdings Limited (hereinafter referred to as “Oricell Therapeutics”), a China-based company dedicated to the development of innovative immuno-oncology therapies, announced that it has recently completed a US$45 million Series B1 financing round following a US$125 million Series B financing in July 2022. The proceeds will primarily be used to support the clinical development of its core products in international markets. This round of financing was jointly led by RTW Investments, a globally renowned industry investor, and QIA (Qatar Investment Authority), with continued investment from existing shareholders such as Qiming Venture Partners and C&D Emerging Investment.

Ms. Yang Huanfeng, Chairman and Chief Executive Officer of Oricell TherapeuticsExpressed: "We are very grateful for the recognition from RTW and QIA, and also very thankful for the support from our existing shareholders. The successful completion of this round of financing reflects the investors' affirmation of Oricell Therapeutics' achievements in recent years in core product development, technology platform construction, and other aspects, as well as their continued optimism about the company’s long-term future. The firm support from investors has greatly encouraged the Oricell team."

After eight years of accumulation and沉淀, Qrigincell Therapeutics' self-developed CAR-T technology platform and its core products have gained further clinical validation. Following the debut of the company's first core product, Ori-C101, on the international stage at the 2021 ASCO (American Society of Clinical Oncology) Annual Meeting, the company’s exposure in the global new drug market continued to increase in 2022 and 2023, drawing extensive attention from global investors. Despite city-wide lockdowns due to the pandemic in 2022, the team overcame numerous challenges and worked tirelessly to achieve all anticipated milestones.

In addition to Ori-C101 receiving approval from China's NMPA to initiate registration clinical trials, in June 2022, the company delivered oral presentations on its OriCAR-017 therapy at the 2022 ASCO Annual Meeting and the 2022 EHA (European Hematology Association) Annual Meeting. In October of the same year, OriCAR-017 was granted "ODD" (Orphan Drug Designation) by the U.S. FDA. By the end of January 2023, the clinical follow-up data of OriCAR-017 was published in the internationally renowned clinical medical journal, *The Lancet Haematology*. Since initiating its Series B financing, Oricell Therapeutics Holdings Limited has simultaneously embarked on a red chip restructuring process, aiming to develop Oricell into an international innovative pharmaceutical enterprise with leading technological and product advantages.

Yang HuanfengFurther stated: "I feel extremely fortunate and reassured that the addition of new investors RTW and QIA in the B1 round will bring us more international resources and support. In the future development process, the Oricell team will always adhere to our original mission of developing innovative therapies with global clinical value. We will accelerate the registration and clinical development of our leading products in both China and the U.S., enhance our innovation capabilities in product development across these two regions, optimize production processes as well as supply chain operation management, reduce costs while improving efficiency. We aim to reward the trust and support of our shareholders with outstanding achievements and meet the needs of clinicians and patients with high-quality products."

RTW Roderick Wong M.D., the co-lead investor, stated"RTW has always been committed to cutting-edge treatment solutions in the field of tumor immunotherapy. As a long-term investor in both primary and secondary markets, we have continuously followed the development of Oricell Therapeutics and have had the privilege of witnessing the company’s milestones achieved in 2022. We are highly honored to collaborate with Oricell Therapeutics in this B1 round of financing. Leveraging the resources we have accumulated over the years in the United States, we aim to empower the company. Moving forward, we will work hand-in-hand with the company's team to provide better treatment options for more cancer patients worldwide and create greater social value."

RTW Investments, LP, headquartered in New York with offices in Shanghai and London, is a global life sciences investment and innovation company focused on transformative and disruptive innovative technologies in the biopharmaceutical and medical technology fields. As a leading partner to both industry and academia, RTW combines deep scientific expertise with a solution-oriented investment approach to advance emerging medical therapies by building, supporting, and empowering companies or academic institutions. For more information about RTW, please visit www.rtwfunds.com.

Qatar Investment Authority ("QIA") is the sovereign wealth fund of the State of Qatar. Established in 2005, QIA is responsible for investing and managing the country’s reserve funds. QIA is one of the largest and most active sovereign wealth funds globally. It invests across various asset classes and regions, forming partnerships with leading institutions worldwide to build a globally diversified investment portfolio with a long-term outlook, aiming to achieve sustainable returns and contribute to the prosperity of the State of Qatar.

Qiming Venture Partners, founded in 2006, has successively established offices in Shanghai, Beijing, Suzhou, Hong Kong (China), Seattle, Boston, and the San Francisco Bay Area. Currently, Qiming Venture Partners manages 11 US dollar funds and 7 RMB funds, with total managed assets under management reaching 9.4 billion US dollars. Since its establishment, it has focused on investing in outstanding enterprises in the early and growth stages of the Technology and Consumer (T&C), and Healthcare industries.

C&D Emerging Investment, established in 2014, is a professional equity asset management institution under the Xiamen C&D Group, a "Fortune Global 500" company. With the mission of "creating new value and helping more emerging enterprises achieve better development," the company focuses on new economic fields such as healthcare, advanced manufacturing, TMT/consumer sectors.

Qrigincell Therapeutics, founded in 2015, is a Chinese innovative pharmaceutical company dedicated to the development of tumor cell immunotherapy products through self-innovative technology platforms. To date, the company has applied for over a hundred patents (including six PCTs) and has been granted ten.

OriCell Therapeutics, with the mission of developing accessible and effective drugs to meet unmet global clinical needs, has independently innovated and built several patented technology platforms based on tumor cell immunotherapy, such as Ori®Ab and Ori®CAR. The company has made breakthroughs in overcoming the efficacy bottleneck for treating solid tumors by focusing on antibody screening and optimization, improving the tumor immune microenvironment, and enhancing T-cell infiltration and sustained killing capacity. The exploratory clinical research data of the company's first CAR-T product targeting GPC-3 was positively received at the 2021 ASCO Annual Meeting and obtained IND approval from NMPA in September 2022. Clinical research data for OriCAR-017, a product targeting GPRC5D for the treatment of relapsed or refractory multiple myeloma, was accepted for oral presentation at the 2022 ASCO/EHA Annual Meetings. Subsequently, the product received Orphan Drug Designation from the U.S. FDA in October 2022, with follow-up data published in January 2023 in the international clinical medicine journal, The Lancet Haematology. OriCell Therapeutics’ first self-developed bispecific antibody drug targeting the immune checkpoint (PD-L1/4-1BB), YN051 (ATG101), was licensed to Antengene (B.6996) for further development under a deal worth $142 million in upfront and milestone payments. Phase I registrational clinical trials for this project have been initiated in Australia, the United States, and China.

Currently, Qrigincell Therapeutics has more than 10 cell drug pipelines for cancer treatment. The key focus includes indications with broad therapeutic needs such as liver cancer, gastric cancer, pancreatic cancer, cholangiocarcinoma, ovarian cancer, non-small cell lung cancer, and multiple myeloma. Adhering to the corporate vision of "becoming a creator of innovative, globally leading tumor immunotherapy drugs," Qrigincell Therapeutics has built an international team specializing in product development, manufacturing, quality management, and clinical development. It has also established production facilities and quality testing and management systems that comply with GMP standards. Leveraging its self-innovative technology platforms, the company will continue to explore and develop effective, differentiated, and cost-accessible innovative cellular immunotherapy drugs for cancer treatment. It aims to seize the opportunities presented by "innovative drugs, made in China" to continuously create new prospects.

In July 2022, Oricell Therapeutics completed a Series B financing round with a total amount exceeding 1.2 billion US dollars.